Floatz logo

msc1936369b

Pilocytic Astrocytoma

Day One Biopharmaceuticals, Inc.Phase 1Active
CC
40/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
25/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Pilocytic Astrocytoma cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
Novartis Pharmaceuticals
Phase 2BB
Carboplatin
Novartis Pharmaceuticals
Phase 2BB
gsk1120212
Novartis Pharmaceuticals
Phase 4BB
Dabrafenib
Novartis Pharmaceuticals
Phase 4BB
Inno-206
Washington University School of Medicine
Phase 2CCC

View all 10 →

Same molecule, other indications

msc1936369b is also rated in:

cutaneous melanomaDormant
CCC
Indicative ·
52 / 100
View asset →
breast cancerDormant
CC
Indicative ·
46 / 100
View asset →
acute myeloid leukemiaDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →